GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » Cash-to-Debt

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Cash-to-Debt : 0.51 (As of Sep. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aerie Pharmaceuticals's cash to debt ratio for the quarter that ended in Sep. 2022 was 0.51.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Aerie Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2022.

The historical rank and industry rank for Aerie Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

AERI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.26   Med: 1.32   Max: No Debt
Current: 0.51

During the past 11 years, Aerie Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.26. And the median was 1.32.

AERI's Cash-to-Debt is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.94 vs AERI: 0.51

Aerie Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Aerie Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Aerie Pharmaceuticals Cash-to-Debt Chart

Aerie Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.02 No Debt 1.50 1.07 0.54

Aerie Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.54 0.58 0.55 0.51

Competitive Comparison of Aerie Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Aerie Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aerie Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aerie Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Aerie Pharmaceuticals's Cash-to-Debt falls into.



Aerie Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Aerie Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Aerie Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Sep. 2022 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aerie Pharmaceuticals  (NAS:AERI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Aerie Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.
Executives
Peter Frederick Lang officer: Chief Financial Officer AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese officer: Vice President of Finance AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley officer: CHRO & VP, Corp Services 15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten officer: Interim CFO AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski officer: Chief Scientific Officer 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell director 2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander officer: Chief R&D Officer C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino officer: Chief Financial Officer
Vicente Jr Anido director, officer: Chief Executive Officer 1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro officer: President and COO 15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618